Trident Lifeline (543616)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 117.33% and profit growth of 54.12% show strong recent momentum.
• P/E of 16.56 is reasonable, and PEG of 0.19 suggests the market is not paying aggressively for growth.
• ROCE of 18.12% indicates efficient use of capital relative to the small-cap pharma segment.
• Piotroski F-Score of 7/9 points to sound fundamentals and improving financial health.

Concerns

• Missing data on promoter holding, book value, ROE, and debt/equity limits transparency and full financial assessment.
• No dividend means shareholders depend entirely on capital appreciation and reinvestment quality.
• Very high growth may be unsustainable in pharmaceuticals, especially if driven by a low base or one-off orders.
• Small market cap of ₹326 crore can lead to volatility and limited institutional interest.

AI Analysis

Let me look at Trident Lifeline as a business, not a ticker. On its face, this is a small pharmaceutical company selling at ₹279.85 with a market cap of ₹326 crore and a P/E of 16.56. For a business whose profits rose 54% and sales grew 117%, that is not an expensive ticket. The PEG ratio of 0.19 screams cheap if the growth is real and durable. But Graham taught me to treat growth estimates with suspicion; a PEG that low usually means the market doubts the growth rate will last. The latest quarter shows sales of ₹26 crore and net profit of ₹5 crore. If I annualize that, it suggests roughly ₹20 crore in earnings, which matches the P/E. The return on capital employed of 18.12% is respectable, and a Piotroski F-Score of 7 out of 9 tells me the fundamentals are improving, not deteriorating. That gives me some confidence in financial health. Still, I am uncomfortable with what I do not know: no book value, no return on equity, no debt-to-equity, and no promoter holding figure. A 7/9 Piotroski score is a good screen, but a score is not a moat. Pharmaceutical is a competitive field; high growth often comes from one product or one contract and can reverse quickly. There is no dividend, so the small shareholder's return depends entirely on management allocating capital wisely. If the quality and execution are there, this is a Fast Grower on a reasonable multiple. If growth slows, the market may re-rate it harshly. I would want to understand the source of the growth before committing, and I would watch the next few quarters to see whether sales and profit can be sustained.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer